{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:54:06Z","timestamp":1788360846686,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["No. 202301AY070001-047"],"award-info":[{"award-number":["No. 202301AY070001-047"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Xingdian Talent Support Program and 535 Talent Project of First Affiliated Hospital of Kunming Medical University","award":["No.2023535D07"],"award-info":[{"award-number":["No.2023535D07"]}]},{"name":"Yunnan Clinical Medical Center for Endocrine and Metabolic Diseases","award":["No. YWLCYXZXXYS20221005"],"award-info":[{"award-number":["No. YWLCYXZXXYS20221005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03810-5","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T08:06:41Z","timestamp":1745568401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anlotinib inhibits c-MET and ITGA2 in the treatment of anaplastic thyroid carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Shunshun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruochuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"issue":"1","key":"3810_CR1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12943-022-01658-x","volume":"21","author":"Z PAN","year":"2022","unstructured":"PAN Z, XU T, BAO L, et al. CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment [J]. Mol Cancer. 2022;21(1):190.","journal-title":"Mol Cancer"},{"issue":"3","key":"3810_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KEBEBEWE BIBLE K C","year":"2021","unstructured":"BIBLE K C KEBEBEWE, BRIERLEY J, et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid Cancer [J]. Thyroid. 2021;31(3):337\u201386.","journal-title":"Thyroid"},{"key":"3810_CR3","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.2147\/OTT.S305196","volume":"14","author":"L GUI","year":"2021","unstructured":"GUI L, LIU S, ZHANG Y, et al. A remarkable and durable response to sintilimab and anlotinib in the First-Line treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: A case report [J]. Onco Targets Ther. 2021;14:2741\u20136.","journal-title":"Onco Targets Ther"},{"issue":"9","key":"3810_CR4","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.7863\/ultra.15.09058","volume":"35","author":"JH HAHN S Y, SHIN","year":"2016","unstructured":"HAHN S Y, SHIN JH. Description and comparison of the sonographic characteristics of poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma [J]. J Ultrasound Med. 2016;35(9):1873\u20139.","journal-title":"J Ultrasound Med"},{"issue":"1","key":"3810_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/thy.2017.0285","volume":"28","author":"PC IYER","year":"2018","unstructured":"IYER PC, DADU R, FERRAROTTO R, et al. Real-World experience with targeted therapy for the treatment of anaplastic thyroid carcinoma [J]. Thyroid. 2018;28(1):79\u201387.","journal-title":"Thyroid"},{"issue":"5","key":"3810_CR6","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1148\/rg.2016150206","volume":"36","author":"T KELIL","year":"2016","unstructured":"KELIL T, KERALIYA A R, HOWARD SA, et al. Current concepts in the molecular genetics and management of thyroid cancer: an update for radiologists [J]. Radiographics. 2016;36(5):1478\u201393.","journal-title":"Radiographics"},{"issue":"1","key":"3810_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"HAUGEN B R","year":"2016","unstructured":"HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid Cancer [J]. Thyroid. 2016;26(1):1\u2013133.","journal-title":"Thyroid"},{"key":"3810_CR8","doi-asserted-by":"publisher","first-page":"626076","DOI":"10.3389\/fonc.2021.626076","volume":"11","author":"Y SU","year":"2021","unstructured":"SU Y, CHENG S, QIAN J, et al. Case report: anlotinib therapy in a patient with recurrent and metastatic RAIR-DTC harboring coexistent TERT promoter and BRAF(V600E) mutations [J]. Front Oncol. 2021;11:626076.","journal-title":"Front Oncol"},{"issue":"20","key":"3810_CR9","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1158\/1078-0432.CCR-22-3406","volume":"29","author":"Y CHI","year":"2023","unstructured":"CHI Y, ZHENG X, ZHANG Y, et al. Anlotinib in locally advanced or metastatic Radioiodine-Refractory differentiated thyroid carcinoma: A randomized, Double-Blind, multicenter phase II trial [J]. Clin Cancer Res. 2023;29(20):4047\u201356.","journal-title":"Clin Cancer Res"},{"key":"3810_CR10","doi-asserted-by":"crossref","unstructured":"MUNTEAN C, SOLOMON A, CIPAIAN R C et al. The efficacy and safety of anlotinib in the treatment of thyroid cancer: A systematic review [J]. J Clin Med, 2025, 14(2).","DOI":"10.3390\/jcm14020338"},{"key":"3810_CR11","doi-asserted-by":"publisher","first-page":"107067","DOI":"10.1016\/j.oraloncology.2024.107067","volume":"159","author":"Y SONG","year":"2024","unstructured":"SONG Y, ZHANG Y, BAI Y, et al. Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study [J]. Oral Oncol. 2024;159:107067.","journal-title":"Oral Oncol"},{"issue":"3","key":"3810_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41416-021-01340-x","volume":"125","author":"J LIANG","year":"2021","unstructured":"LIANG J, JIN Z, KUANG J, et al. The role of anlotinib-mediated EGFR Blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis [J]. Br J Cancer. 2021;125(3):390\u2013401.","journal-title":"Br J Cancer"},{"issue":"1","key":"3810_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1530\/ERC-17-0558","volume":"26","author":"X RUAN","year":"2019","unstructured":"RUAN X, SHI X. Antitumor effects of anlotinib in thyroid cancer [J]. Endocr Relat Cancer. 2019;26(1):153\u201364.","journal-title":"Endocr Relat Cancer"},{"key":"3810_CR14","doi-asserted-by":"crossref","unstructured":"WU J, LIANG J, LIU R et al. Autophagic Blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer [J]. Endocr Relat Cancer, 2023, 30(9).","DOI":"10.1530\/ERC-23-0036"},{"key":"3810_CR15","doi-asserted-by":"crossref","unstructured":"WU J, LIANG J, LIU R et al. ERRATUM: autophagic Blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer [J]. Endocr Relat Cancer, 2025, 32(2).","DOI":"10.1530\/ERC-23-0036e"},{"issue":"1","key":"3810_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y SUN","year":"2016","unstructured":"SUN Y, NIU W. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors [J]. J Hematol Oncol. 2016;9(1):105.","journal-title":"J Hematol Oncol"},{"key":"3810_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-030-47189-7_2","volume":"1270","author":"A ZAMBELLI","year":"2021","unstructured":"ZAMBELLI A, BIAMONTI G. HGF\/c-Met signalling in the tumor microenvironment [J]. Adv Exp Med Biol. 2021;1270:31\u201344.","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"3810_CR18","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/cncr.11638","volume":"98","author":"HC NARDONE","year":"2003","unstructured":"NARDONE HC, ZIOBER A F, LIVOLSI V A, et al. c-Met expression in tall cell variant papillary carcinoma of the thyroid [J]. Cancer. 2003;98(7):1386\u201393.","journal-title":"Cancer"},{"issue":"4","key":"3810_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/biomedicines2040263","volume":"2","author":"L RUCO","year":"2014","unstructured":"RUCO L. The pathogenetic role of the HGF\/c-Met system in papillary carcinoma of the thyroid [J]. Biomedicines. 2014;2(4):263\u201374.","journal-title":"Biomedicines"},{"key":"3810_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cca.2021.12.017","volume":"525","author":"HH YANG X, LIAO H Y, ZHANG","year":"2022","unstructured":"YANG X, LIAO H Y, ZHANG HH. Roles of MET in human cancer [J]. Clin Chim Acta. 2022;525:69\u201383.","journal-title":"Clin Chim Acta"},{"issue":"4","key":"3810_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1023\/A:1023768811842","volume":"22","author":"PC MA","year":"2003","unstructured":"MA PC, MAULIK G, CHRISTENSEN J, et al. c-Met: structure, functions and potential for therapeutic Inhibition [J]. Cancer Metastasis Rev. 2003;22(4):309\u201325.","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"3810_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1530\/ERC-19-0403","volume":"27","author":"K LEE","year":"2020","unstructured":"LEE K, LEE SH, KIM W, et al. Dsg2-mediated c-Met activation in anaplastic thyroid cancer motility and invasion [J]. Endocr Relat Cancer. 2020;27(11):601\u201314.","journal-title":"Endocr Relat Cancer"},{"issue":"5\u20136","key":"3810_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/sj.bjc.6690406","volume":"80","author":"JD BERGSTR\u00f6M","year":"1999","unstructured":"BERGSTR\u00f6M JD, DIAZ DE ST\u00e5HL HERMANSSONA. Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture [J]. Br J Cancer. 1999;80(5\u20136):650\u20136.","journal-title":"Br J Cancer"},{"issue":"9","key":"3810_CR24","doi-asserted-by":"publisher","first-page":"10472","DOI":"10.18632\/oncotarget.7228","volume":"7","author":"J WILLIAMSON A J, DOSCAS M E, YE","year":"2016","unstructured":"WILLIAMSON A J, DOSCAS M E, YE J, et al. The Sonic Hedgehog signaling pathway stimulates anaplastic thyroid cancer cell motility and invasiveness by activating Akt and c-Met [J]. Oncotarget. 2016;7(9):10472\u201385.","journal-title":"Oncotarget"},{"issue":"4","key":"3810_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ijc.32180","volume":"145","author":"G WANG","year":"2019","unstructured":"WANG G, SUN M, JIANG Y, et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual Blockade of VEGFR2 and MET in osteosarcoma [J]. Int J Cancer. 2019;145(4):979\u201393.","journal-title":"Int J Cancer"},{"issue":"6","key":"3810_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2174\/1871520620666200718235748","volume":"21","author":"X TANG","year":"2021","unstructured":"TANG X, ZHENG Y. Anlotinib inhibits cell proliferation, migration and invasion via suppression of c-Met pathway and activation of ERK1\/2 pathway in H446 cells [J]. Anticancer Agents Med Chem. 2021;21(6):747\u201355.","journal-title":"Anticancer Agents Med Chem"},{"key":"3810_CR27","doi-asserted-by":"publisher","first-page":"994528","DOI":"10.3389\/fcell.2022.994528","volume":"10","author":"J STANISLOVAS","year":"2022","unstructured":"STANISLOVAS J. c-Met-integrin cooperation: mechanisms, tumorigenic effects, and therapeutic relevance [J]. Front Cell Dev Biol. 2022;10:994528.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"3810_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41580-024-00777-1","volume":"26","author":"J CHASTNEY M R, KAIVOLA","year":"2025","unstructured":"CHASTNEY M R, KAIVOLA J, LEPP\u00e4NEN VM, et al. The role and regulation of integrins in cell migration and invasion [J]. Nat Rev Mol Cell Biol. 2025;26(2):147\u201367.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"41","key":"3810_CR29","doi-asserted-by":"publisher","first-page":"E8685","DOI":"10.1073\/pnas.1701821114","volume":"114","author":"A JAHANGIRI","year":"2017","unstructured":"JAHANGIRI A, NGUYEN A, CHANDRA A, et al. Cross-activating c-Met\/\u03b21 integrin complex drives metastasis and invasive resistance in cancer [J]. Proc Natl Acad Sci U S A. 2017;114(41):E8685\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3810_CR30","doi-asserted-by":"crossref","unstructured":"LAU D, WADHWA H. SUDHIR S, Role of c-Met\/\u03b21 integrin complex in the metastatic cascade in breast cancer [J]. JCI Insight, 2021, 6(12).","DOI":"10.1172\/jci.insight.138928"},{"issue":"13","key":"3810_CR31","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1158\/1078-0432.CCR-16-2180","volume":"23","author":"J DONG","year":"2017","unstructured":"DONG J, WANG R, REN G, et al. HMGA2-FOXL2 Axis regulates metastases and Epithelial-to-Mesenchymal transition of chemoresistant gastric Cancer [J]. Clin Cancer Res. 2017;23(13):3461\u201373.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3810_CR32","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.18632\/aging.102954","volume":"12","author":"L MA","year":"2020","unstructured":"MA L, SUN Y, LI D, et al. Overexpressed ITGA2 contributes to Paclitaxel resistance by ovarian cancer cells through the activation of the AKT\/FoxO1 pathway [J]. Aging. 2020;12(6):5336\u201351.","journal-title":"Aging"},{"key":"3810_CR33","doi-asserted-by":"crossref","unstructured":"CHASTNEY M R, KAIVOLA J, LEPP\u00e4NEN VM et al. The role and regulation of integrins in cell migration and invasion [J]. Nat Rev Mol Cell Biol, 2024.","DOI":"10.1038\/s41580-024-00777-1"},{"issue":"4","key":"3810_CR34","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s12253-018-0551-0","volume":"25","author":"L ZHANG","year":"2019","unstructured":"ZHANG L, HUANG Y, LING J, et al. Is integrin subunit alpha 2 expression a prognostic factor for liver carcinoma?? A validation experiment based on bioinformatics analysis [J]. Pathol Oncol Res. 2019;25(4):1545\u201352.","journal-title":"Pathol Oncol Res"},{"issue":"8","key":"3810_CR35","doi-asserted-by":"publisher","first-page":"12884","DOI":"10.1002\/jcp.27953","volume":"234","author":"J GONG","year":"2019","unstructured":"GONG J, LU X, XU J, et al. Coexpression of UCA1 and ITGA2 in pancreatic cancer cells target the expression of miR-107 through focal adhesion pathway [J]. J Cell Physiol. 2019;234(8):12884\u201396.","journal-title":"J Cell Physiol"},{"key":"3810_CR36","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.2741\/2863","volume":"13","author":"DE HERDT M J","year":"2008","unstructured":"DE HERDT M J, BAATENBURG DE JONG R J. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma [J]. Front Biosci. 2008;13:2516\u201326.","journal-title":"Front Biosci"},{"issue":"1","key":"3810_CR37","doi-asserted-by":"publisher","first-page":"E62","DOI":"10.1210\/jc.2013-2994","volume":"99","author":"M GARG","year":"2014","unstructured":"GARG M, KANOJIA D, OKAMOTO R, et al. Laminin-5\u03b3-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR [J]. J Clin Endocrinol Metab. 2014;99(1):E62\u201372.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3810_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11658-022-00409-6","volume":"28","author":"L ZHANG","year":"2023","unstructured":"ZHANG L, XU M, ZHANG W, et al. Three-dimensional genome landscape comprehensively reveals patterns of Spatial gene regulation in papillary and anaplastic thyroid cancers: a study using representative cell lines for each cancer type [J]. Cell Mol Biol Lett. 2023;28(1):1.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"3810_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41392-021-00489-4","volume":"6","author":"Y ZHANG","year":"2021","unstructured":"ZHANG Y, JING Y, WANG Y, et al. NAT10 promotes gastric cancer metastasis via N4-acetylated COL5A1 [J]. Signal Transduct Target Ther. 2021;6(1):173.","journal-title":"Signal Transduct Target Ther"},{"key":"3810_CR40","doi-asserted-by":"publisher","first-page":"837581","DOI":"10.3389\/fonc.2022.837581","volume":"12","author":"C WANG","year":"2022","unstructured":"WANG C, WANG Y, FU Z, et al. MiR-29b-3p inhibits migration and invasion of papillary thyroid carcinoma by downregulating COL1A1 and COL5A1 [J]. Front Oncol. 2022;12:837581.","journal-title":"Front Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03810-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T08:06:45Z","timestamp":1745568405000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03810-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3810"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03810-5","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the animal experiments were approved by the Animal Experiment Ethics Review Committee of Kunming Medical University (Approval number: kmmu20231505), and the animals were humanely cared for according to the standards of the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}